NewPhase Successfully Completed Small Mammal Pre-clinical Trials of a Cancer Treatment That Transforms Cancer to a Treatable Chronic Ailment

Company backed by a $6m from private investors, is now raising financing for the Phase I human trials

Apr 11, 2016, 08:00 ET from NewPhase

TEL AVIV, Israel, April 11, 2016 /PRNewswire/ --

In his State of the Union address, President Obama proposed a "moonshot" to find a cure for cancer. He stated "For the loved ones we've all lost, for the family we can still save, let's make America the country that cures cancer once and for all," 

An Israeli start-up company, NewPhase, started by an engineer is transforming cancer from a potentially lethal disease to a treatable chronic ailment.

NewPhase have successfully completed small mammal pre-clinial trials of Safety, Toxicity and Efficacy (4T1 breast cancer's mice cell line) and have now started large mammals Safety and Toxicity trials. The company plan to begin Phase I FDA human trials in Q1 2017.

In 2011, Dr. Rafael (Rafi) Hof, a PhD in Mechanical Engineering, went through the very unpleasant experience of taking care of his mother during her battle with cancer. He began to read to better understand cancer and realized that there was no systematic 100% effective treatment. As he read more about cancer and discussed this with oncologists, two characteristics of cancer came together in his mind and at that point he understood that if combined into a treatment, they would provide a systematic treatment for cancer effective significantly more than the current technology and drugs.

In 2013, together with a colleague, Ofer Shalev, they established NewPhase to develop and commercialize treatment.

The treatment technology is based on NewPhases' patented Sarah nano-particle, named after Rafi's mother (SaNP). SaNP utilizes two characteristics of cancer cells, namely that cancer cells are anaerobic consuming 28 times more glucose than normal cells (Warburg effect) and that the membrane of all cells burst when heated to 46˚C.   

SaNP, which contain glucose, uses the glucose as a navigation mechanism to attach themselves to cancer cells 28 times more than to normal cells. When exposed to radio frequency (RF) energy (which is harmless to the human body) at a 13.56 Mhz frequency, SaNP absorbs this energy to achieve phase change at a predetermined temperature (50˚C) that causes the destruction of cancer cell membranes - thus killing cancer cells, and only cancer cells.

In the development of the SaNP, the founder closely worked with Dr. Arnoldo Cyjon, Deputy Head of Oncology at Assaf Harofe Hospital, who said: "Currently, treatment of disseminated cancer is primarily done by chemotherapy with all the inherent adverse side effects. Recently developed biologic and immune related technologies show high responses in selected cancer patients but following a relatively short period of disease control the majority of patients experience reoccurrence of their disease. The uniqueness of New Phase SaNP treatment is that it causes cancer cell death, sparing normal cells thus greatly reducing the side effects suffered by patients compared to those treated with conventional approaches. Additionally, SaNP can be applied reputedly with no development of resistance."

Watch the video: https://www.youtube.com/watch?v=BZ6h6szr4eM&feature=youtu.be


Contact:
Mr. Ofer Shalev
Tel: +972-54-5677717
Email: ofers@newphase.co.il

SOURCE NewPhase